Poolbeg Pharma (LON:POLB) Sets New 12-Month High – Still a Buy?

Poolbeg Pharma PLC (LON:POLB) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 9 and last traded at GBX 8.70, with a volume of 3810007 shares trading hands. The stock had previously closed at GBX 8.65.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a report on Monday, July 13th.

Poolbeg Pharma Price Performance

The stock’s 50 day moving average price is GBX 7.11 and its two-hundred day moving average price is GBX 5.52. The firm has a market capitalization of £64.89 million, a price-to-earnings ratio of -9.04 and a beta of 1.80.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.